Anna Iwanicka-Dabrowska

Warsaw, MZ, Poland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Underrated, Unvaccinated, Untreated: A Multinational Registry Analysis of Human Metapneumovirus in Hematological Malignancy, Insights From EPICOVIDEHA/EPIRESEHA Registry.

Underrated, Unvaccinated, Untreated: A Multinational Registry Analysis of Human Metapneumovirus in Hematological Malignancy, Insights From EPICOVIDEHA/EPIRESEHA Registry.

Journal: Open forum infectious diseases

Published: September 24, 2025

The long-term efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in the treatment of primary central nervous system lymphoma: A real-world report from the Polish Lymphoma Research Group.

The long-term efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in the treatment of primary central nervous system lymphoma: A real-world report from the Polish Lymphoma Research Group.

Journal: European journal of cancer (Oxford, England : 1990)

Published: August 16, 2025

Beyond the Usual Suspects: RSV Infection in Patients With Hematological Malignancies Compared to Influenza and SARS-COV-2-A Report From the EPICOVIDEHA/EPIRESEHA Registry.

Beyond the Usual Suspects: RSV Infection in Patients With Hematological Malignancies Compared to Influenza and SARS-COV-2-A Report From the EPICOVIDEHA/EPIRESEHA Registry.

Journal: American journal of hematology

Published: July 22, 2025

Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial.

Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial.

Journal: Blood

Published: February 20, 2025

Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023-2024: EPICOVIDEHA-EPIFLUEHA Report.

Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023-2024: EPICOVIDEHA-EPIFLUEHA Report.

Journal: American journal of hematology

Published: October 16, 2024

Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results.

Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 19, 2024

DLBCL: who is high risk and how should treatment be optimized?

DLBCL: who is high risk and how should treatment be optimized?

Journal: Blood

Published: July 10, 2023

Safety and efficacy of induction immunochemotherapy with rituximab, methotrexate, ifosfamide, and vincristine (R-MIV) in patients with primary CNS lymphoma including recent COVID-19 pandemic experience.

Safety and efficacy of induction immunochemotherapy with rituximab, methotrexate, ifosfamide, and vincristine (R-MIV) in patients with primary CNS lymphoma including recent COVID-19 pandemic experience.

Journal: British journal of haematology

Published: November 16, 2022

Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation-ineligible relapsed and refractory diffuse large B-cell lymphoma.

Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation-ineligible relapsed and refractory diffuse large B-cell lymphoma.

Journal: British journal of haematology

Published: January 14, 2022

High efficacy of intensive immunochemotherapy for primary mediastinal B-cell lymphoma with prolonged follow up.

High efficacy of intensive immunochemotherapy for primary mediastinal B-cell lymphoma with prolonged follow up.

Journal: Scientific reports

Published: December 08, 2021

Efficacy of siltuximab in the treatment of idiopathic multicentric castleman disease, the first Polish, real-world experience with long-term observation.

Efficacy of siltuximab in the treatment of idiopathic multicentric castleman disease, the first Polish, real-world experience with long-term observation.

Journal: Leukemia & lymphoma

Published: June 23, 2021

First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4.

First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4.

Journal: British journal of haematology

Published: August 12, 2019

Showing 1-12 of 15

Last Updated: 09/26/2026